Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BND-35 Alone and in Combination With Nivolumab or Cetuximab in Advanced Solid Tumors
NCT06274437Phase 1Terminated
- Sponsor
- Biond Biologics
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BND-35 in solid tumor (5 arms), sponsored by Biond Biologics. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events at 24 months, Proportion of patients who discontinued study treatment due to TEAEs at 34 months and 2 more. Started Jun 2024; status: terminated.
02
Drugs
BND-35
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06274437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06274437.